Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program

NEW HAVEN, Conn., Oct. 3, 2024. Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and...

Articles similaires

Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH

drugs.com - 01/Oct 00:10

SAN MATEO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company...

Eirion Therapeutics Announces Results of First-in-Human Clinical Trial Evaluating Ready-to-Use Liquid Injectable Neuromodulator AI-09 for the Treatment of Wrinkles

drugs.com - 02/Oct 03:10

WOBURN, Mass., Oct. 1, 2024. Eirion Therapeutics Inc., a biopharmaceutical company focused on developing innovative aesthetic prescription product...

Chronic Pulmonary Infections Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Teva Pharma, Merck, F. Hoffmann-La Roche, Novartis, GSK

mountaintoday.in - 01/Oct 11:48

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Chronic Pulmonary Infections pipeline constitutes 10+ key companies...

AI-Driven Drug Discovery Achieves Milestone with Insilico Medicine’s Phase IIa Success in Treating Pulmonary Fibrosis

unite.ai - 26/Sep 19:40

Insilico Medicine’s Generative AI-designed Drug ISM001-055 Shows Promising Results in Phase IIa Clinical Trials In a breakthrough for AI-powered...

Thryv Therapeutics Granted FDA Orphan Drug Designation for LQT-1213 in Long QT Syndrome Treatment

drugs.com - 01/Oct 00:10

Montreal, Quebec – October 1, 2024 – Thryv Therapeutics Inc., a clinical stage biotech company dedicated to developing treatments for rare...

FDA Approves Dupixent for Chronic Obstructive Pulmonary Disease

drugs.com - 01/Oct 22:48

TUESDAY, Oct. 1, 2024 -- The U.S. Food and Drug Administration has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with...

MaxCyte signs strategic platform license with Kamau Therapeutics to accelerate the development of cell therapies for genetic diseases

news.medical.net - 23/Sep 04:33

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and...

Les derniers communiqués

Adobe Brings Conversational AI to Trillions of PDFs with the New AI Assistant in Reader and Acrobat
Adobe - 21/02/2024
Laura Frigenti takes the Helm as Chief Executive Officer of the Global Partnership for Education
Global Partnership for Education - 05/12/2022

Rubriques :